PPARγ Activation: A Potential Treatment For Pulmonary Hypertension-Reference-Cited by-同舟云学术

PPARγ Activation: A Potential Treatment For Pulmonary Hypertension

Published:2009-12-23 Issue:12 Volume:1 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Hansmann Georg¹,Zamanian Roham T.²³

Affiliation:

1. Department of Cardiology, Children’s Hospital Boston, Harvard Medical School, Boston, MA, USA.

2. Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University, Stanford, CA, USA.

3. Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, USA.

Abstract

Pharmacological activation of the transcription factor PPARγ affects the expression of key genes involved in the development of pulmonary hypertension (PH), subsequently has a variety of beneficial effects in the vasculature, and hence might be a powerful treatment of PH.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference36 articles.

1. Inflammation, Growth Factors, and Pulmonary Vascular Remodeling

2. Cellular and Molecular Basis of Pulmonary Arterial Hypertension

3. Genetics and Genomics of Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-γ Activation

5. An antiproliferative BMP-2/PPARγ/apoE axis in human and murine SMCs and its role in pulmonary hypertension

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation;ACS Pharmacology & Translational Science;2024-08-01

2. SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy;Circulation Research;2024-06-21

3. Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function;Cardiovascular Drugs and Therapy;2024-06-07

4. Pulmonary hypertension and insulin resistance: a mechanistic overview;Frontiers in Endocrinology;2024-01-04

5. Transcription factors in the pathogenesis of pulmonary arterial hypertension—Current knowledge and therapeutic potential;Frontiers in Cardiovascular Medicine;2023-01-06